Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended follow-up of melanoma patients treated with fianlimab plus cemiplimab
2024-517729-20-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and fianlimab in melanoma, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Overall survival. Planned start Jul 2025; status: authorised.
02
Drugs
cemiplimabfianlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-517729-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517729-20-00.